Pavilion Holdings Group said it is seeking $10 million for new venture group, Pavilion Ventures, which will take over all of its current medical device projects.
PHG has acted as an incubator for many of the companies it has worked with, having spun out 3 venture/angel backed companies in the last 10 months alone. Pavilion helps move smaller companies’ products to regulatory clearance and commercialization, and potentially gets the company to a point of exit.
The launch of Pavilion Ventures is a move to have projects under its own name and umbrella. PV plans to raise approximately $10 million to fund its pipeline, and will operate and manage the emerging portfolio collectively. This product portfolio includes reversible endoscopic treatment of obesity, tissue ablation including renal denervation for hypertension and disposable infusion pumps, according to a press release.
“We plan to offer the opportunity to participate in the growth of a diversified portfolio of companies that is balanced between shorter-term, lower-risk projects and longer-term projects with much higher projected exits. Our intent is to deploy the proven Pavilion Model on a broader scale to maximize medium and long-term return. We believe this approach overcomes many of the shortcomings of the current financing landscape for new medical technologies,” PHG Partner/Co-Founder and Pavilion Ventures CEO Lishan Aklog said in prepared remarks.
